Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

S. Rosen, Lee; Gordon, David; Simon Tchekmedyian, N.; Yanagihara, Ronald; Hirsh, Vera; Krzakowski, Maciej; Pawlicki, Marek; de Souza, Paul; Zheng, Ming; Urbanowitz, Gladys; J. Reitsma, Dirk; J. Seaman, John; behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, On

doi:10.1002/cncr.20308

Public

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

Published in Cancer • May 6, 2004

Authors:

Lee S. Rosen

David Gordon

N. Simon Tchekmedyian

Abstract

BACKGROUND: The authors previously reported the efficacy of a dose of 4 mg of zoledronic acid in reducing skeletal complications in patients with bone metastases secondary to lung carcinoma and other solid tumors (except carcinomas of the breast and prostate). In the current study, they update these...

Subject

Zoledronic acid

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!